Anti-Insulin-Like Growth Factor Strategies in Breast Cancer

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 3, 2004, Pages 54-63

  Jerome, Lori ^b   Shiry, Laura ^b   Leyland Jones, Brian ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH HORMONE RELEASING FACTOR ANTAGONIST; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHA IR3; MONOCLONAL ANTIBODY EM 164; MONOCLONAL ANTIBODY IGF IR; PACLITAXEL; PEGVISOMANT; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN RECEPTOR; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW;

EID: 2142761658     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.01.007     Document Type: Article

References (102)

1. Marshman E, Streuli CH: Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 4:231-239, 2002
2. Strange KS, Wilkinson D, Emerman JT: Mitogenic properties of insulin-like growth factors I and II, insulin-like growth factor binding protein-3 and epidermal growth factor on human breast epithelial cells in primary culture. Breast Cancer Res Treat 75:203-212, 2002
3. Laban C, Bustin SA, Jenkins PJ: The GH-IGF-1 axis and breast cancer. Trends Endocrinol Metab 14:28-34, 2003
4. Pollak MN: Endocrine effects of IGF-I on normal and transformed breast epithelial cells: Potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47:209-217, 1998
5. Surmacz E: Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5:95-105, 2000
6. Peyrat JP, Bonneterre J: Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat 22:59-67, 1992
7. Papa V, Gliozzo B, Clark GM, et al: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736-3740, 1993
8. Pezzino V, Papa V, Milazzo G, et al: Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann N Y Acad Sci 784:189-201, 1996
9. Resnik JL, Reichart DB, Huey K, et al: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58:1159-1164, 1998
10. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215-244, 2000
11. Quinn KA, Treston AM, Unsworth EJ, et al: Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271:11477-11483, 1996
12. Firth SM, Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854, 2002
13. Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396, 1998
14. Li BD, Khosravi MJ, Berkel HJ, et al: Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 91:736-739, 2001
15. Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10:68-91, 1989
16. Arany E, Afford S, Strain AJ, et al: Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 79:1871-1876, 1994
17. Olivecrona H, Hilding A, Ekstrom C, et al: Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: Serum levels and hepatic messenger ribonucleic acid responses in humans. J Clin Endocrinol Metab 84:553-560, 1999
18. Sepp-Lorenzino L: Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 47:235-253, 1998
19. Zhang X, Yee D: Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2:170-175, 2000
20. Yamauchi K, Pessin JE: Insulin receptor substrate-1 (IRS1) and Shc compete for a limited pool of Grb2 in mediating insulin downstream signaling. J Biol Chem 269:31107-31114, 1994
21. Sell C, Dumenil G, Deveaud C, et al: Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14:3604-3612, 1994
22. Sell C, Rubini M, Rubin R, et al: Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 90:11217-11221, 1993
23. Morrione A, DeAngelis T, Baserga R: Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes. J Virol 69:5300-5303, 1995
24. Moschos SJ, Mantzoros CS: The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 63:317-332, 2002
25. Nolan CM, Kyle JW, Watanabe H, et al: Binding of insulin-like growth factor II (IGF-II) by human cation-independent mannose 6-phosphate receptor/IGF-II receptor expressed in receptor-deficient mouse L cells. Cell Regul 1:197-213, 1990
26. Sciacca L, Mineo R, Pandini G, et al: In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21:8240-8250, 2002
27. Frasca F, Pandini G, Scalia P, et al: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288, 1999
28. Sciacca L, Costantino A, Pandini G, et al: Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene 18:2471-2479, 1999
29. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34, 1995
30. Pandini G, Frasca F, Mineo R, et al: Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277:39684-39695, 2002
31. Baxter RC: Insulin-like growth factor binding proteins in the human circulation: A review. Horm Res 42:140-144, 1994
32. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472-1489, 2000
33. Coverley JA, Martin JL, Baxter RC: The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3. Endocrinology 141:564-570, 2000
34. Barreca A, Artini PG, Cesarone A, et al: Interrelationships between follicle stimulating hormone and the growth hormone-insulin-like growth factor-IGF-binding proteins axes in human granulosa cells in culture. J Endocrinol Invest 19:35-42, 1996
35. Li YM, Schacher DH, Liu Q, et al: Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 138:362-368, 1997
36. Karas M, Danilenko M, Fishman D, et al: Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells. J Biol Chem 272:16514-16520, 1997
37. Valentinis B, Bhala A, DeAngelis T, et al: The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9:361-367, 1995
38. Rajah R, Valentinis B, Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181-12188, 1997
39. Gill ZP, Perks CM, Newcomb PV, et al: Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 272:25602-25607, 1997
40. Rozen F, Zhang J, Pollak M: Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 13:865-869, 1998
41. Rajah R, Lee KW, Cohen P: Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: Role of Bcl-2 phosphorylation. Cell Growth Differ 13:163-171, 2002
42. Gucev ZS, Oh Y, Kelley KM, et al: Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 56:1545-1550, 1996
43. Colston KW, Perks CM, Xie SP, et al: Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 20:157-162, 1998
44. Buckbinder L, Talbott R, Velasco-Miguel S, et al: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649, 1995
45. Gooch JL, Van den Berg CL, Yee D: Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-Proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56:1-10, 1999
46. Surmacz E, Guvakova MA, Nolan MK, et al: Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 47:255-267, 1998
47. Lee AV, Weng CN, Jackson JG, et al: Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152:39-47, 1997
48. Huynh H, Yang X, Pollak M:. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271:1016-1021, 1996
49. Skaar TC, Baumrucker CR: Regulation of insulin-like growth factor binding protein secretion by a murine mammary epithelial cell line. Exp Cell Res 209:183-188, 1993
50. Mathieu M, Vignon F, Capony F, et al: Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: A receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Endocrinol 5:815-822, 1991
51. Werner H, Le Roith D: The insulin-like growth: factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 8:71-92, 1997
52. Peyrat JP, Bonneterre J, Hecquet B, et al: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A:492-497, 1993
53. Barni S, Lissoni P, Brivio F, et al: Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 80:212-215, 1994
54. Favoni RF, de Cupis A, Perrotta A, et al: Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: Mutual relationship and possible correlations with patients' hormonal status. J Cancer Res Clin Oncol 121:674-682, 1995
55. Szepeshazi K, Schally AV, Armatis P, et al: Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 142:4371-4378, 2001
56. Kahan Z, Varga JL, Schally AV, et al: Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat 60:71-79, 2000
57. Jungwirth A, Schally AV, Pinski J, et al: Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci U S A 94:5810-5813, 1997
58. Braczkowski R, Schally AV, Plonowski A, et al: Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on insulin-like growth factor II. Cancer 95:1735-1745, 2002
59. Jungwirth A, Schally AV, Pinski J, et al: Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer 75:1585-1592, 1997
60. Weckbecker G, Tolcsvai L, Liu R, et al: Preclinical studies on the anticancer activity of the somatostatin analog octreotide (SMS 201-995). Digestion 54:98-103, 1993 (suppl 1)
61. O'Byrne KJ, Dobbs N, Propper DJ, et al: Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 79:1413-1418, 1999
62. Ingle JN, Suman VJ, Kardinal CG, et al: A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85:1284-1292, 1999
63. Bajetta E, Procopio G, Ferrari L, et al: A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 94:299-304, 2002
64. McCutcheon IE, Flyvbjerg A, Hill H, et al: Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94:487-492, 2001
65. Friend KE: Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res 11:S121-S123, 2001 (suppl A)
66. Resnicoff M, Abraham D, Yutanawiboonchai W, et al: The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55:2463-2469, 1995
67. Resnicoff M, Tjuvajev J, Rotman HL, et al: Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA. J Exp Ther Oncol 1:385-389, 1996
68. Scotlandi K, Avnet S, Benini S, et al: Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 101:11-16, 2002
69. Neuenschwander S, Roberts CT Jr, LeRoith D: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 136:4298-4303, 1995
70. Chernicky CL, Yi L, Tan H, et al: Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 7:384-395, 2000
71. Arteaga CL, Kitten LJ, Coronado EB, et al: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418-1423, 1989
72. Kato H, Faria TN, Stannard B, et al: Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem 268:2655-2661, 1993
73. Arteaga CL: Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 22: 101-106, 1992
74. Li SL, Liang SJ, Guo N, et al: Single-chain antibodies against human insulin-like growth factor I receptor: Expression, purification, and effect on tumor growth. Cancer Immunol Immunother 49:243-252, 2000
75. Sachdev D, Li SL, Hartell JS, et al: A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63:627-635, 2003
76. Maloney EK, McLaughlin JL, Dagdigian NE, et al: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63: 5073-5083, 2003
77. Yee D: The insulin-like growth factor system as a treatment target in breast cancer. Semin Oncol 29:86-95, 2002 (suppl 11)
78. Lu D, Zhang H, Ludwig D, et al: Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with fully human recombinant bispecific antibodies. J Biol Chem 279:2856-2865, 2004
79. Ullrich A, Gray A, Tam AW, et al: Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5:2503-2512, 1986
80. Parrizas M, Gazit A, Levitzki A, et al: Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138:1427-1433, 1997
81. Blum G, Gazit A, Levitzki A: Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39:15705-15712, 2000
82. Blum G, Gazit A, Levitzki A: Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 278:40442-40454, 2003
83. Surmacz E: Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22:6589-6597, 2003
84. D'Ambrosio C, Ferber A, Resnicoff M, et al: A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 56:4013-4020, 1996
85. Dunn SE, Ehrlich M, Sharp NJ, et al: A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58:3353-3361, 1998
86. McGuire WL Jr, Jackson JG, Figueroa JA, et al: Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84:1336-1341, 1992
87. Figueroa JA, Sharma J, Jackson JG, et al: Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 157:229-236, 1993
88. Yee D, Jackson JG, Kozelsky TW, et al: Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Differ 5:73-77, 1994
89. Van den Berg CL, Cox GN, Stroh CA, et al: Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 33:1108-1113, 1997
90. McCaig C, Fowler CA, Laurence NJ, et al: Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells. Br J Cancer 86:1963-1969, 2002
91. Hollowood AD, Lai T, Perks CM, et al: IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer 88:336-341, 2000
92. Perks CM, McCaig C, Clarke JB, et al: A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. Biochem Biophys Res Commun 294:988-994, 2002
93. Butt AJ, Firth SM, King MA, et al: Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 275:39174-39181, 2000
94. Shiry LJ, Blouin MJ, Lenhert S, et al: Radiosensitizing effect of rhIGFBP-3 on MCF-7 breast cancer cells in vitro. Horm Res 58:266, 2002 (abstr P20)
95. Fowler CA, Perks CM, Newcomb PV, et al: Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int J Cancer 88:448-453, 2000
96. Lee DY, Yi HK, Hwang PH, et al: Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells. Biochem Biophys Res Commun 294:480-486, 2002
97. Lu Y, Zi X, Zhao Y, et al: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857, 2001
98. Guvakova MA, Surmacz E: Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 57:2606-2610, 1997
99. Huynh HT, Pollak M: Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53:5585-5588, 1993
100. Campbell MJ, Woodside JV, Secker-Walker J, et al: IGF status is altered by tamoxifen in patients with breast cancer. Mol Pathol 54:307-310, 2001
101. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
102. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998